Cassava Sciences Inc
SAVA
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
49.8% upsideUndervalued by 49.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $63.77 Million |
|---|---|
| Enterprise Value | $-22,806,577.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.88 |
| Beta | -0.84 |
| Outstanding Shares | 48,297,000 |
Return
| Return on Equity | -114.32% |
|---|---|
| Return on Assets | -71.89% |
| Return on Invested Capital | -14.23% |
Valuation & Multiples
| P/E Ratio | -0.95 |
|---|---|
| PEG | 1.71 |
| Price to Sales | - |
| Price to Book Ratio | 1.32 |
| Enterprise Value to Revenue | -27.15 |
| Enterprise Value to EBIT | 2.35 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7924▼ 14.54% |
|---|---|
| Total Calls | 494,300▼ 34.72% |
| Total Puts | 391,700▼ 44.84% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 28.25%▼ 0.31% |
|---|---|
| Total Invested | $23.06M▼ 15.57% |
| Investors Holding | 107▼ 9.00% |
ESG Score
No data
About Cassava Sciences Inc
29 employees
CEO: Remi Barbier refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
Relevant Senate Committees
Controls taxation policy (impacting profitability) and entitlement spending, crucially influencing Medicare and Medicaid drug pricing and coverage, which directly impacts a pharmaceutical company's revenue and market access.
Directly regulates the FDA and NIH, which are critical for drug approval, research funding, and overall pharmaceutical and biotech sector oversight. Committee members would likely possess highly material non-public information.
Crucial for pharmaceutical companies due to its oversight of intellectual property (patents, vital for drug exclusivity) and antitrust enforcement, which can impact M&A activity within the sector.
Although advisory, its investigations into drug pricing and long-term care for older Americans create significant headline risk and influence market sentiment and policy discussions that directly impact the company, especially if targeting age-related diseases.